Immunovant, Inc.
For the period ended Dec 31, 2025. Filed Feb 6, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Dec 31, 2025 · Filed Feb 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Other Information
Insider Trading Arrangements
During the quarter ended December 31, 2025, no director or officer (as defined in Rule 16a-1 under the Exchange Act)adopted orterminated any Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (in each case, as defined in Item 408(a) of Regulation S-K), except as disclosed below.
| Name and Title | Action | Date | Duration of Trading Arrangement | Rule 10b5-1 Trading Arrangement (Y/N)(1) | Number of Ordinary Shares to be Sold |
|---|---|---|---|---|---|
| Atul Pande, Director | Adoption | December 26, 2025 | March 27, 2026 – February 26, 2027 | Y | 21,000 |
| Robert Susman, Director | Adoption | December 30, 2025 | May 1, 2026 – July 2, 2026 | Y | 2,502 |
(1) Contract, instruction, or written plan to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.